Inhibitory interactions between TILs and tumor cells are blocked by anti-PD-L1, while the use of anti-CTLA-4 likely both promotes the activation of new tumor-specific T cells and overcomes regulatory T cell inhibitory pathways. This evidence concerns the gene CTLA4 and neoplasm.